日本结直肠内镜黏膜下剥离术后直接口服抗凝药类型与迟发性出血分析
基于日本47家机构2012至2021年34,455例结直肠内镜黏膜下剥离术的回顾性研究,比较直接口服抗凝药(DOAC)与华法林相关迟发性出血率。达比加群出血率高于其他DOAC,仅利伐沙班出血率显著低于华法林。肝素桥接、直肠部位和手术时间≥55分钟为DOAC组迟发性出血独立危险因素。
要点
- 达比加群迟发性出血率18.26%,显著高于阿哌沙班10.08%、依度沙班7.73%和利伐沙班7.21%。
- 仅利伐沙班出血率显著低于华法林(7.21% vs 11.76%,P=.033)。
- DOAC组危险因素:肝素桥接、直肠部位、手术时间≥55分钟。
核心结论
- 达比加群相关迟发性出血率高于其他直接口服抗凝药。
- 仅利伐沙班相关迟发性出血率显著低于华法林。
研究设计与样本
- 多中心回顾性研究(ABCD-J研究),纳入日本47家机构2012至2021年结直肠内镜黏膜下剥离术病例。
- 直接口服抗凝药组1019处病变,华法林组459处病变,共评估34,455例内镜黏膜下剥离术病例。
主要发现
- 直接口服抗凝药组平均肿瘤大小29.6±14.0 mm,华法林组30.3±16.4 mm。
- 达比加群出血率18.26%,显著高于阿哌沙班10.08%(P=.029)、依度沙班7.73%(P=.001)和利伐沙班7.21%(P<.001)。
- 利伐沙班出血率7.21%显著低于华法林11.76%(P=.033)。
- 直接口服抗凝药组多因素分析:肝素桥接治疗OR 2.18(95%CI 1.27-3.73,P=.005)、直肠部位OR 2.01(95%CI 1.28-3.16,P=.002)、手术时间≥55分钟OR 2.43(95%CI 1.49-3.95,P<.001)为迟发性出血显著危险因素。
- 直接口服抗凝药组迟发性出血风险:1个显著危险因素OR 2.13(95%CI 1.30-3.50),2个显著危险因素OR 4.53(95%CI 2.52-8.15)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Reported rates of delayed bleeding (DB) after endoscopic resection using direct oral anticoagulants (DOACs) are high and heterogeneous. This large-scale multicenter study analyzed cases of DB after colorectal endoscopic submucosal dissection related to various types of DOACs in Japan (the ABCD-J study) with those associated with warfarin. METHODS: We retrospectively reviewed 1019 lesions in patients treated with DOACs and 459 lesions in patients treated with warfarin among 34,455 endoscopic submucosal dissection cases from 47 Japanese institutions between 2012 and 2021. The DB rate (DBR) with each DOAC was compared with that with warfarin. Risk factors for DB in patients treated with DOACs or warfarin were also investigated. RESULTS: The mean tumor sizes in the DOAC and warfarin groups were 29.6 ± 14.0 and 30.3 ± 16.4 mm, respectively. In the DOAC group, the DBR with dabigatran (18.26%) was significantly higher than that with apixaban (10.08%, P = .029), edoxaban (7.73%, P = .001), and rivaroxaban (7.21%, P < .001). Only rivaroxaban showed a significantly lower DBR than warfarin (11.76%, P = .033). In the multivariate analysis, heparin bridging therapy (odds ratio [OR], 2.18; 95% confidence interval [CI], 1.27-3.73, P = .005), rectal location (2.01, 1.28-3.16, P = .002), and procedure time ≥55 minutes (2.43, 1.49-3.95, P < .001) were significant risk factors for DB in the DOAC group. The DB risk in the DOAC group (OR, (95% CI)) was 2.13 (1.30-3.50) and 4.53 (2.52-8.15) for 1 and 2 significant risk factors, respectively. CONCLUSIONS: Dabigatran was associated with a higher DBR than other DOACs, and only rivaroxaban was associated with a significantly lower DBR than warfarin.
引用
- Yoshida N, Hayashi Y, Togo D, et al. An Analysis of Delayed Bleeding in Cases of Colorectal Endoscopic Submucosal Dissection Due to Types of Direct Oral Anticoagulants in Japan. Clin Gastroenterol Hepatol. 2023. PMID: 37743040. doi:10.1016/j.cgh.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。